Please use this identifier to cite or link to this item:
Title: Toward a single-dose cure for buruli ulcer
Authors: Thomas, Sangeeta Susan
Kalia, Nitin Pal
Ruf, Marie-Thérèse
Pluschke, Gerd
Pethe, Kevin
Keywords: Science::Medicine
Issue Date: 2020
Source: Thomas, S. S., Kalia, N. P., Ruf, M., Pluschke, G. & Pethe, K. (2020). Toward a single-dose cure for buruli ulcer. Antimicrobial Agents and Chemotherapy, 64(9).
Project: NMRC/CBRG/0083/2015
Journal: Antimicrobial Agents and Chemotherapy
Abstract: A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
ISSN: 0066-4804
DOI: 10.1128/AAC.00727-20
Rights: © 2020 American Society for Microbiology (ASM). All rights reserved. This paper was published in Antimicrobial Agents and Chemotherapy and is made available with permission of American Society for Microbiology (ASM).
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:IGS Journal Articles

Files in This Item:
File Description SizeFormat 
Antimicrobial Agents and Chemotherapy-2020-Thomas-e00727-20.full.pdf441.84 kBAdobe PDFView/Open

Page view(s)

Updated on Jul 21, 2021


Updated on Jul 21, 2021

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.